Allopurinol
Adult Acute Lymphoblastic Leukemia
Explore 66 assets in Adult Acute Lymphoblastic Leukemia →Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Roswell Park Cancer Institute
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01564277CT.gov Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | — | Terminated | — | — | — |
NCT00061945CT.gov Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | — | Completed | — | — | — |
NCT00199043CT.gov Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult Acute Lymphoblastic Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Allopurinol (this asset) | Roswell Park Cancer Institute | P3 | B · 62 |
| Mercaptopurine Anhydrous | Shanxi Bethune Hospital | P4 | BBB |
| Cytarabine | PETHEMA Foundation | P4 | BBB |
| Dexasone | Shanxi Bethune Hospital | P4 | BBB |
| Cyclophosphamide | The First Affiliated Hospital of Zhengzhou University | P4 | BBB |
| Methotrexate | PETHEMA Foundation | P4 | BBB |
| Vindesine | Shanxi Bethune Hospital | P4 | BBB |
| Adriamycin | University of Washington | P4 | BBB |
| Asparaginase | Institute of Hematology & Blood Diseases Hospital, China | P4 | BBB |
+42 more in the Adult Acute Lymphoblastic Leukemia cohort
Other indications for Allopurinol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Manic Bipolar Affective Disorder | — | P4 | BB · 65 |
| Essential Hypertension | — | P3 | B · 62 |
| Leukemia | — | P2 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Allopurinol in Adult Acute Lymphoblastic Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/allopurinol-adult-acute-lymphoblastic-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →